Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Abbott Laboratories shares valued at $337,116 were sold by Blount Sally E. on Apr 30 ’25. At $129.66 per share, Blount Sally E. sold 2,600 shares. The insider’s holdings dropped to 34,058 shares worth approximately $4.48 million following the completion of this transaction.
Also, SALLY E BLOUNT purchased 2,600 shares, netting a total of over 337,116 in proceeds.
Before that, Earnhardt Lisa D had sold 91,167 shares from its account. In a trade valued at $12,199,968, the EVP AND GROUP PRESIDENT traded Abbott Laboratories shares for $133.82 each. Upon closing the transaction, the insider’s holdings decreased to 91,167 shares, worth approximately $9.46 million.
As published in their initiating research note from Oppenheimer on October 08, 2024, Abbott Laboratories [ABT] has been an Outperform and the price target has been revised to $130. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid September. As of July 30, 2024, Edward Jones has decreased its “Buy” rating to a “Hold” for ABT. Earlier on May 30, 2024, Goldman initiated its rating. Their recommendation was “a Buy” for ABT stock.
Analyzing ABT Stock Performance
During the last five days, there has been a drop of approximately -1.39%. Over the course of the year, Abbott Laboratories shares have jumped approximately 16.26%. Shares of the company reached a 52-week high of $141.23 on 03/04/25 and a 52-week low of $110.86 on 01/15/25.
Support And Resistance Levels for Abbott Laboratories (ABT)
According to the 24-hour chart, there is a support level at 130.82, which, if violated, would cause prices to drop to 130.14. In the upper region, resistance lies at 132.53. The next price resistance is at 133.56. RSI (Relative Strength Index) is 49.32 on the 14-day chart, showing neutral technical sentiment.
